Gilead Sciences has reportedly struck a deal with Anthem (ANTM) for Hepatitis C drug. Anthem has chosen Gilead's Harvoni as the primary option for patients with the most common type of Hepatitis C, dropping the drug from rival pharmaceutical company AbbVie Inc. Anthem chose Harvoni over AbbVIes Viekira Pak for its favorable pricing and clinical differentiators, such as a simpler dosing. Harvoni is one pill a day, compared with Viekira Pak's 4- to 6-pill dosing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.3 USD | +2.32% |
|
+6.62% | -9.52% |
07-17 | Gilead Sciences Chief Medical Officer Merdad Parsey to Leave | MT |
07-17 | Gilead Sciences Chief Medical Officer to Step Down | DJ |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.52% | 89.25B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences Inks Deal with Anthem for Hepatitis C Drug